ATP5F1B and hepatocellular carcinoma: Moreover, we found that Gboxin, an F1FO ATP synthase inhibitor, could disturb the interaction between TOMM34 and ATP5B, leading to impairment of the compensatory adaptive process and tumor metastasis in both HCC cell lines and PDX models.